| |
Immune checkpoint inhibitors offer significant survival benefit, yet many patients do not respond to these treatments. Dosing optimization offers hope. Learn how to maximize therapeutic efficacy and minimize toxicity of ICIs in our guide. .png)
|
|
Today’s Big NewsOct 1, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
| By James Waldron Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China and $400 million in series A funds. |
|
|
|
By Nick Paul Taylor Shattuck Labs has hammered another nail into the coffin of CD47. After seeing a “modest” effect on survival in blood cancer, the biotech axed its candidate, pivoted to a preclinical program and gave 40% of its employees pink slips. |
By James Waldron IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. Now, the company has become the latest to join a hot trend in cell therapy biotech—pivoting from oncology to autoimmune disease. |
By Nick Paul Taylor Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer vaccine data fell short of the runaway success needed to transform its fortunes. |
|
This white paper delves into key challenges in ADC development and explores new drug product capabilities in cytotoxic drug development and manufacturing, accelerating timelines to IND filing and beyond. 
|
|
By Fraiser Kansteiner Metsera is teaming up with generics and specialty drug maker Amneal Pharmaceuticals, which will now serve as the biotech’s “preferred supply partner” for developed markets. |
By Gabrielle Masson BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets identified by the biotech’s RNA platform designed to help create treatments for genetic diseases. |
By Darren Incorvaia After a six-month beta testing period, the European Clinical Trials Information Network is rolling out its patient recruitment platform across Europe. |
By Darren Incorvaia The company seeks to spare our guts from antibiotics using genetically modified microbes and a unique regulatory approach. |
By Fraiser Kansteiner Pfizer has sold 640 million shares in Haleon for 380 pence (roughly $5.09) apiece. The sale amounts to a total value of 2.43 billion pounds sterling (about $3.26 billion) and follows a similar move in March. |
By Dave Muoio The drugmaker told HRSA Monday it has "no choice" but to forego a requirement for DSH covered entities to obtain their drug discounts via rebate. |
By Joseph Keenan Piramal Pharma Solutions, a unit of Indian CDMO Piramal Pharma, plans to spend $80 million to expand its sterile injectables manufacturing facility in Lexington, Kentucky. |
Fierce podcasts Don’t miss an episode |
| In this week's "The Top Line," Fierce journalists discuss key issues from promising but debated lung cancer data at recent conferences. |
|
|---|
|
|
|
Optimize Bioprocessing with Scalable Solutions – Achieve Higher Yields, Greater Purity, and Faster Time-to-market. 
|
|
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| Submissions Deadline Sept 12th |
|
|
| |
|
